<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Beta-lactamase,Carbon-nitrogen non-peptide hydrolases,Carbon-nitrogen non-peptide hydrolases,2006,AMP deaminase,Adenosine deaminase,Amidohydrolase,Aminoglycoside,Aminoglycosides,Aminohydrolase,Amoxicillin" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Beta-lactamase - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Beta-lactamase</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <div class="messagebox cleanup metadata plainlinks">
<table style="width:100%; background:none">
<tr>
<td width="60px"><a href="../../../b/r/o/Image%7EBroom_icon.svg_73f7.html" class="image" title=""><img src="../../../upload/shared/thumb/2/2c/Broom_icon.svg/40px-Broom_icon.svg.png" alt="" width="40" height="40" longdesc="../../../b/r/o/Image%7EBroom_icon.svg_73f7.html" /></a></td>
<td><b>This article may require <a href="../../../c/l/e/Wikipedia%7ECleanup_89e0.html" title="Wikipedia:Cleanup">cleanup</a> to meet Wikipedia's <a href="../../../m/a/n/Wikipedia%7EManual_of_Style_350a.html" title="Wikipedia:Manual of Style">quality standards</a>.</b><br />
<small>Please discuss this issue on the <a href="../../../b/e/t/Talk%7EBeta-lactamase_2e72.html" title="Talk:Beta-lactamase">talk page</a> or <a href="http://en.wikipedia.org../../../b/e/t/Beta-lactamase.html" class="external text" title="http://en.wikipedia.org../../../b/e/t/Beta-lactamase.html" rel="nofollow">replace this tag</a> with a <a href="../../../t/e/m/Wikipedia%7ETemplate_messages_Cleanup_ae6e.html#Specific_issues" title="Wikipedia:Template messages/Cleanup">more specific message</a>.<br />
This article has been tagged since <b>October 2006</b>.</small></td>
</tr>
</table>
</div>
<table border="0" bgcolor="#FFFFFF" cellpadding="2" cellspacing="0" align="right" width="305" style="border:2px solid #e7dcc3;margin-left:3px">
<tr>
<th bgcolor="#E7DCC3" colspan="2">Beta-lactamase</th>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../h/u/g/HUGO_3046.html" title="HUGO">Symbol(s)</a>:</td>
<td style="border-top:2px solid #e7dcc3;" width="220"><a href="http://www.gene.ucl.ac.uk/nomenclature/data/get_data.php?hgnc_id=HGNC:16468" class="external text" title="http://www.gene.ucl.ac.uk/nomenclature/data/get_data.php?hgnc_id=HGNC:16468" rel="nofollow">LACTB</a></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" colspan="2" align="center"><b><a href="../../../g/e/n/Genetics.html" title="Genetics">Genetic data</a></b></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../l/o/c/Locus_%28genetics%29.html" title="Locus (genetics)">Locus</a>:</td>
<td style="border-top:2px solid #e7dcc3;" width="220"><a href="../../../c/h/r/Chromosome_15_%28human%29.html" title="Chromosome 15 (human)">Chr. 15</a> <i><a href="http://www.ncbi.nlm.nih.gov/Omim/getmap.cgi?chromosome=15q22" class="external text" title="http://www.ncbi.nlm.nih.gov/Omim/getmap.cgi?chromosome=15q22" rel="nofollow">q22.1</a></i></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" colspan="2" align="center"><b>Database Links</b></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../e/c/_/EC_number_9459.html" title="EC number">EC number</a>:</td>
<td style="border-top:1px solid #e7dcc3;" width="220"><a href="http://www.expasy.org/enzyme/3.5.2.6" class="external text" title="http://www.expasy.org/enzyme/3.5.2.6" rel="nofollow">3.5.2.6</a></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../e/n/t/Entrez.html" title="Entrez">Entrez</a>:</td>
<td style="border-top:1px solid #e7dcc3;" width="220"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&amp;cmd=retrieve&amp;dopt=default&amp;list_uids=114294&amp;rn=1" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&amp;cmd=retrieve&amp;dopt=default&amp;list_uids=114294&amp;rn=1" rel="nofollow">114294</a></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../o/m/i/OMIM_6457.html" title="OMIM">OMIM</a>:</td>
<td style="border-top:1px solid #e7dcc3;" width="220"><a href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=608440&amp;rn=1" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=608440&amp;rn=1" rel="nofollow">608440</a></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../n/c/b/NCBI_db71.html" title="NCBI">RefSeq</a>:</td>
<td style="border-top:1px solid #e7dcc3;" width="220"><a href="http://genome.cse.ucsc.edu/cgi-bin/hgGene?org=Human&amp;hgg_gene=NM_171846&amp;rn=1" class="external text" title="http://genome.cse.ucsc.edu/cgi-bin/hgGene?org=Human&amp;hgg_gene=NM_171846&amp;rn=1" rel="nofollow">NM_171846</a></td>
</tr>
<tr valign="top">
<td bgcolor="#E7DCC3" width="85"><a href="../../../s/w/i/Swiss-Prot_eb2f.html" title="Swiss-Prot">UniProt</a>:</td>
<td style="border-top:1px solid #e7dcc3;" width="220"><a href="http://www.expasy.org/uniprot/P83111" class="external text" title="http://www.expasy.org/uniprot/P83111" rel="nofollow">P83111</a></td>
</tr>
</table>
<p><b>Beta-lactamase</b> is a type of <a href="../../../e/n/z/Enzyme.html" title="Enzyme">enzyme</a> (<a href="../../../e/c/_/EC_number_9459.html" title="EC number">EC</a> <a href="http://www.expasy.org/cgi-bin/nicezyme.pl?3.5.2.6" class="external text" title="http://www.expasy.org/cgi-bin/nicezyme.pl?3.5.2.6" rel="nofollow">3.5.2.6</a>) produced by some bacteria that is responsible for their <a href="../../../a/n/t/Antibiotic_resistance.html" title="Antibiotic resistance">resistance</a> to <a href="../../../b/e/t/Beta-lactam_antibiotic.html" title="Beta-lactam antibiotic">beta-lactam antibiotics</a> like <a href="../../../p/e/n/Penicillin.html" title="Penicillin">penicillins</a>, <a href="../../../c/e/p/Cephalosporin.html" title="Cephalosporin">cephalosporins</a>, <a href="../../../c/e/p/Cephamycin.html" title="Cephamycin">cephamycins</a> and <a href="../../../c/a/r/Carbapenem.html" title="Carbapenem">carbapenems</a>. These <a href="../../../a/n/t/Antibiotic.html" title="Antibiotic">antibiotics</a> have a common element in their molecular structure: a four-atom ring known as a <a href="../../../b/e/t/Beta-lactam.html" title="Beta-lactam">beta-lactam</a>. The lactamase enzyme breaks that ring open, deactivating the molecule's antibacterial properties.</p>
<p>Beta-lactamases produced by gram-positive organisms are usually secreted.</p>
<p>The structure of a <i><a href="../../../s/t/r/Streptomyces.html" title="Streptomyces">Streptomyces</a></i> Î² lactamase is given by <a href="../../../p/r/o/Protein_Data_Bank_1de2.html" title="Protein Data Bank">PDB</a> <a href="http://www.rcsb.org/pdb/cgi/explore.cgi?pdbId=1BSG" class="external text" title="http://www.rcsb.org/pdb/cgi/explore.cgi?pdbId=1BSG" rel="nofollow">1BSG</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Penicillinase"><span class="tocnumber">1</span> <span class="toctext">Penicillinase</span></a></li>
<li class="toclevel-1"><a href="#Classification_of_Beta_Lactamase"><span class="tocnumber">2</span> <span class="toctext">Classification of Beta Lactamase</span></a>
<ul>
<li class="toclevel-2"><a href="#Functional_Classification.07UNIQ242ca9c52404fa0d-nowiki-00000015-QINU2.07UNIQ242ca9c52404fa0d-nowiki-00000016-QINU"><span class="tocnumber">2.1</span> <span class="toctext">Functional Classification[2]</span></a>
<ul>
<li class="toclevel-3"><a href="#Group_1"><span class="tocnumber">2.1.1</span> <span class="toctext">Group 1</span></a>
<ul>
<li class="toclevel-4"><a href="#GROUP_1:_CEPHALOSPORINASE.2C_Molecular_Class_C_.28not_inhibited_by_clavulanic_acid.29"><span class="tocnumber">2.1.1.1</span> <span class="toctext">GROUP 1: CEPHALOSPORINASE, Molecular Class C (not inhibited by clavulanic acid)</span></a></li>
</ul>
</li>
<li class="toclevel-3"><a href="#Group_2"><span class="tocnumber">2.1.2</span> <span class="toctext">Group 2</span></a>
<ul>
<li class="toclevel-4"><a href="#GROUP_2a:_PENICILLINASE.2C_Molecular_Class_A"><span class="tocnumber">2.1.2.1</span> <span class="toctext">GROUP 2a: PENICILLINASE, Molecular Class A</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2b:_BROAD_SPECTRUM.2C_Molecular_Class_A"><span class="tocnumber">2.1.2.2</span> <span class="toctext">GROUP 2b: BROAD SPECTRUM, Molecular Class A</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2be:_EXTENDED_SPECTRUM.2C_Molecular_Class_A"><span class="tocnumber">2.1.2.3</span> <span class="toctext">GROUP 2be: EXTENDED SPECTRUM, Molecular Class A</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2br:_INHIBITOR_RESISTANT.2C_Molecular_Class_A_.28diminished_inhibition_by_clavulanic_acid.29"><span class="tocnumber">2.1.2.4</span> <span class="toctext">GROUP 2br: INHIBITOR RESISTANT, Molecular Class A (diminished inhibition by clavulanic acid)</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2c:_CARBENICILLINASE.2C_Molecular_Class_A"><span class="tocnumber">2.1.2.5</span> <span class="toctext">GROUP 2c: CARBENICILLINASE, Molecular Class A</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2d:_CLOXACILANASE.2C_Molecular_Class_D_or_A"><span class="tocnumber">2.1.2.6</span> <span class="toctext">GROUP 2d: CLOXACILANASE, Molecular Class D or A</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2e:_CEPHALOSPORINASE.2C_Molecular_Class_A"><span class="tocnumber">2.1.2.7</span> <span class="toctext">GROUP 2e: CEPHALOSPORINASE, Molecular Class A</span></a></li>
<li class="toclevel-4"><a href="#GROUP_2f:_CARBAPENAMASE.2C_Molecular_Class_A"><span class="tocnumber">2.1.2.8</span> <span class="toctext">GROUP 2f: CARBAPENAMASE, Molecular Class A</span></a></li>
</ul>
</li>
<li class="toclevel-3"><a href="#Group_3"><span class="tocnumber">2.1.3</span> <span class="toctext">Group 3</span></a>
<ul>
<li class="toclevel-4"><a href="#GROUP_3:_METALLOENZYME.2C_Molecular_Class_B_.28not_inhibited_by_clavulanic_acid.29"><span class="tocnumber">2.1.3.1</span> <span class="toctext">GROUP 3: METALLOENZYME, Molecular Class B (not inhibited by clavulanic acid)</span></a></li>
</ul>
</li>
<li class="toclevel-3"><a href="#Group_4"><span class="tocnumber">2.1.4</span> <span class="toctext">Group 4</span></a>
<ul>
<li class="toclevel-4"><a href="#GROUP_4:_PENICILLINASE.2C_No_Molecular_Class_.28not_inhibited_by_clavulanic_acid.29"><span class="tocnumber">2.1.4.1</span> <span class="toctext">GROUP 4: PENICILLINASE, No Molecular Class (not inhibited by clavulanic acid)</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-2"><a href="#Molecular_Classification"><span class="tocnumber">2.2</span> <span class="toctext">Molecular Classification</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Resistance_in_gram_negative_bacteria"><span class="tocnumber">3</span> <span class="toctext">Resistance in gram negative bacteria</span></a>
<ul>
<li class="toclevel-2"><a href="#Extended_spectrum_beta_lactamase_.28ESBL.29"><span class="tocnumber">3.1</span> <span class="toctext">Extended spectrum beta lactamase (ESBL)</span></a>
<ul>
<li class="toclevel-3"><a href="#Types"><span class="tocnumber">3.1.1</span> <span class="toctext">Types</span></a></li>
<li class="toclevel-3"><a href="#TEM_beta-lactamases_.28class_A.29"><span class="tocnumber">3.1.2</span> <span class="toctext">TEM beta-lactamases (class A)</span></a></li>
<li class="toclevel-3"><a href="#SHV_beta-lactamases_.28class_A.29"><span class="tocnumber">3.1.3</span> <span class="toctext">SHV beta-lactamases (class A)</span></a></li>
<li class="toclevel-3"><a href="#CTX-M_beta-lactamases_.28class_A.29"><span class="tocnumber">3.1.4</span> <span class="toctext">CTX-M beta-lactamases (class A)</span></a></li>
<li class="toclevel-3"><a href="#OXA_beta-lactamases_.28class_D.29"><span class="tocnumber">3.1.5</span> <span class="toctext">OXA beta-lactamases (class D)</span></a></li>
<li class="toclevel-3"><a href="#Others"><span class="tocnumber">3.1.6</span> <span class="toctext">Others</span></a></li>
<li class="toclevel-3"><a href="#Treatment"><span class="tocnumber">3.1.7</span> <span class="toctext">Treatment</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#INHIBITOR_RESISTANT_.CE.B2-LACTAMASES"><span class="tocnumber">3.2</span> <span class="toctext">INHIBITOR RESISTANT Î²-LACTAMASES</span></a></li>
<li class="toclevel-2"><a href="#AmpC_TYPE_.CE.B2-LACTAMASES_.28CLASS_C.29"><span class="tocnumber">3.3</span> <span class="toctext">AmpC TYPE Î²-LACTAMASES (CLASS C)</span></a></li>
<li class="toclevel-2"><a href="#CARBAPENEMASES"><span class="tocnumber">3.4</span> <span class="toctext">CARBAPENEMASES</span></a>
<ul>
<li class="toclevel-3"><a href="#IMP-type_carbapenemases_.28one_of_the_metallo-b-lactamases.29"><span class="tocnumber">3.4.1</span> <span class="toctext">IMP-type carbapenemases (one of the metallo-b-lactamases)</span></a></li>
<li class="toclevel-3"><a href="#VIM_.28Verona_integron-encoded_metallo-b-lactamase.29"><span class="tocnumber">3.4.2</span> <span class="toctext">VIM (Verona integron-encoded metallo-b-lactamase)</span></a></li>
<li class="toclevel-3"><a href="#OXA_.28oxacillinase.29_group_of_.CE.B2-lactamases_.28Class_D.29"><span class="tocnumber">3.4.3</span> <span class="toctext">OXA (oxacillinase) group of Î²-lactamases (Class D)</span></a></li>
<li class="toclevel-3"><a href="#KPC_.28K._pneumoniae_carbapenemase.29_.28Class_A.29"><span class="tocnumber">3.4.4</span> <span class="toctext">KPC (K. pneumoniae carbapenemase) (Class A)</span></a></li>
<li class="toclevel-3"><a href="#CMY_.28Class_C.29"><span class="tocnumber">3.4.5</span> <span class="toctext">CMY (Class C)</span></a></li>
<li class="toclevel-3"><a href="#SME.2C_IMI.2C_NMC_and_CcrA"><span class="tocnumber">3.4.6</span> <span class="toctext">SME, IMI, NMC and CcrA</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1"><a href="#Treatment_of_ESBL.2FAmpC.2Fcarbapenemases"><span class="tocnumber">4</span> <span class="toctext">Treatment of ESBL/AmpC/carbapenemases</span></a>
<ul>
<li class="toclevel-2"><a href="#General_Overview"><span class="tocnumber">4.1</span> <span class="toctext">General Overview</span></a></li>
<li class="toclevel-2"><a href="#According_to_genes"><span class="tocnumber">4.2</span> <span class="toctext">According to genes</span></a>
<ul>
<li class="toclevel-3"><a href="#ESBLs"><span class="tocnumber">4.2.1</span> <span class="toctext">ESBLs</span></a></li>
<li class="toclevel-3"><a href="#Inhibitor-Resistant_.CE.B2-Lactamases"><span class="tocnumber">4.2.2</span> <span class="toctext">Inhibitor-Resistant Î²-Lactamases</span></a></li>
<li class="toclevel-3"><a href="#AmpC"><span class="tocnumber">4.2.3</span> <span class="toctext">AmpC</span></a></li>
<li class="toclevel-3"><a href="#carbapenemases"><span class="tocnumber">4.2.4</span> <span class="toctext">carbapenemases</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#According_to_Species"><span class="tocnumber">4.3</span> <span class="toctext">According to Species</span></a>
<ul>
<li class="toclevel-3"><a href="#E._coli_or_klebsiella"><span class="tocnumber">4.3.1</span> <span class="toctext">E. coli or klebsiella</span></a></li>
<li class="toclevel-3"><a href="#P._aeruginosa"><span class="tocnumber">4.3.2</span> <span class="toctext">P. aeruginosa</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">5</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">6</span> <span class="toctext">See also</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Penicillinase" id="Penicillinase"></a></p>
<h2><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Penicillinase">edit</a>]</span> <span class="mw-headline">Penicillinase</span></h2>
<p>Penicillinase is a particular type of Î² lactamase, showing specificity for <a href="../../../p/e/n/Penicillin.html" title="Penicillin">penicillins</a>, again by <a href="../../../h/y/d/Hydrolysis.html" title="Hydrolysis">hydrolysing</a> the <a href="../../../b/e/t/Beta-lactam.html" title="Beta-lactam">beta-lactam</a> ring. Molecular weights of the various penicillinases tend to cluster near 50,000.</p>
<p>Penicillinase was the first Î²-lactamase to be identified: it was first isolated by Abraham and Chain in 1940 from <i>E. coli</i> even before penicillin entered clinical use<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup> but penicillinase production quickly spread to bacteria that previously did not produce it or only produced it rarely. Penicillinase-resistant Î² lactams such as <a href="../../../m/e/t/Methicillin.html" title="Methicillin">methicillin</a> were developed, but there is now widespread <a href="../../../a/n/t/Antibiotic_resistance.html" title="Antibiotic resistance">resistance</a> to even these (for example, <a href="../../../m/r/s/MRSA_d8a1.html" title="MRSA">MRSA</a>).</p>
<p><a name="Classification_of_Beta_Lactamase" id="Classification_of_Beta_Lactamase"></a></p>
<h2><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Classification of Beta Lactamase">edit</a>]</span> <span class="mw-headline">Classification of Beta Lactamase</span></h2>
<p><a name="Functional_Classification.07UNIQ242ca9c52404fa0d-nowiki-00000015-QINU2.07UNIQ242ca9c52404fa0d-nowiki-00000016-QINU" id="Functional_Classification.07UNIQ242ca9c52404fa0d-nowiki-00000015-QINU2.07UNIQ242ca9c52404fa0d-nowiki-00000016-QINU"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Functional Classification[2]">edit</a>]</span> <span class="mw-headline">Functional Classification<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[2]</a></sup></span></h3>
<p><a name="Group_1" id="Group_1"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Group 1">edit</a>]</span> <span class="mw-headline">Group 1</span></h4>
<p><a name="GROUP_1:_CEPHALOSPORINASE.2C_Molecular_Class_C_.28not_inhibited_by_clavulanic_acid.29" id="GROUP_1:_CEPHALOSPORINASE.2C_Molecular_Class_C_.28not_inhibited_by_clavulanic_acid.29"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 1: CEPHALOSPORINASE, Molecular Class C (not inhibited by clavulanic acid)">edit</a>]</span> <span class="mw-headline">GROUP 1: CEPHALOSPORINASE, Molecular Class C <i>(not inhibited by clavulanic acid)</i></span></h5>
<p>Group 1 are cephalosporinases not inhibited by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a>, belonging to the molecular class C</p>
<p><a name="Group_2" id="Group_2"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Group 2">edit</a>]</span> <span class="mw-headline">Group 2</span></h4>
<p>Group 2 are penicillinases, cephalosporinases, or both inhibited by clavulanic acid, corresponding to the molecular classes A and D reflecting the original TEM and SHV genes. However, because of the increasing number of TEM and SHV derived {beta} lactamases, they were divided into two subclasses, 2a and 2b.</p>
<p><a name="GROUP_2a:_PENICILLINASE.2C_Molecular_Class_A" id="GROUP_2a:_PENICILLINASE.2C_Molecular_Class_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2a: PENICILLINASE, Molecular Class A">edit</a>]</span> <span class="mw-headline">GROUP 2a: PENICILLINASE, Molecular Class A</span></h5>
<p>The <i>2a subgroup</i> contains just penicillinases.</p>
<p><a name="GROUP_2b:_BROAD_SPECTRUM.2C_Molecular_Class_A" id="GROUP_2b:_BROAD_SPECTRUM.2C_Molecular_Class_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2b: BROAD SPECTRUM, Molecular Class A">edit</a>]</span> <span class="mw-headline">GROUP 2b: BROAD SPECTRUM, Molecular Class A</span></h5>
<p><i>2b</i> Opposite to 2a , 2b are broad spectrum {beta} lactamases, meaning that they are capable of inactivating <a href="../../../p/e/n/Penicillins.html" title="Penicillins">penicillins</a> and <a href="../../../c/e/p/Cephalosporins.html" title="Cephalosporins">cephalosporins</a> at the same rate. Furthermore, new subgroups were segregated from subgroup 2b:</p>
<p><a name="GROUP_2be:_EXTENDED_SPECTRUM.2C_Molecular_Class_A" id="GROUP_2be:_EXTENDED_SPECTRUM.2C_Molecular_Class_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2be: EXTENDED SPECTRUM, Molecular Class A">edit</a>]</span> <span class="mw-headline">GROUP 2be: EXTENDED SPECTRUM, Molecular Class A</span></h5>
<p><i>Subgroup 2be</i>, with the letter "e" for extended spectrum of activity, represents the ESBLs, which are capable of inactivating third generation cephalosporins (ceftazidime, cefotaxime, and cefpodoxime) as well as <a href="../../../m/o/n/Monobactams.html" title="Monobactams">monobactams</a> (aztreonam)</p>
<p><a name="GROUP_2br:_INHIBITOR_RESISTANT.2C_Molecular_Class_A_.28diminished_inhibition_by_clavulanic_acid.29" id="GROUP_2br:_INHIBITOR_RESISTANT.2C_Molecular_Class_A_.28diminished_inhibition_by_clavulanic_acid.29"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2br: INHIBITOR RESISTANT, Molecular Class A (diminished inhibition by clavulanic acid)">edit</a>]</span> <span class="mw-headline">GROUP 2br: INHIBITOR RESISTANT, Molecular Class A <i>(diminished inhibition by clavulanic acid)</i></span></h5>
<p>The <i>2br</i> enzymes, with the letter "r" denoting reduced binding to <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a> and <a href="../../../s/u/l/Sulbactam.html" title="Sulbactam">sulbactam</a>, are also called inhibitor resistant TEM derivative enzymes; nevertheless, they are still susceptible to <a href="../../../t/a/z/Tazobactam.html" title="Tazobactam">tazobactam</a>.</p>
<p><a name="GROUP_2c:_CARBENICILLINASE.2C_Molecular_Class_A" id="GROUP_2c:_CARBENICILLINASE.2C_Molecular_Class_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2c: CARBENICILLINASE, Molecular Class A">edit</a>]</span> <span class="mw-headline">GROUP 2c: CARBENICILLINASE, Molecular Class A</span></h5>
<p>Later<i>subgroup 2c</i> was segregated from group 2 because these enzymes inactivate <a href="../../../c/a/r/Carbenicillin.html" title="Carbenicillin">carbenicillin</a> more than <a href="../../../b/e/n/Benzylpenicillin.html" title="Benzylpenicillin">benzylpenicillin</a>, with some effect on <a href="../../../c/l/o/Cloxacillin.html" title="Cloxacillin">cloxacillin</a>.</p>
<p><a name="GROUP_2d:_CLOXACILANASE.2C_Molecular_Class_D_or_A" id="GROUP_2d:_CLOXACILANASE.2C_Molecular_Class_D_or_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2d: CLOXACILANASE, Molecular Class D or A">edit</a>]</span> <span class="mw-headline">GROUP 2d: CLOXACILANASE, Molecular Class D or A</span></h5>
<p><i>Subgroup 2d</i> enzymes inactivate <a href="../../../c/l/o/Cloxacillin.html" title="Cloxacillin">cloxacillin</a> more than <a href="../../../b/e/n/Benzylpenicillin.html" title="Benzylpenicillin">benzylpenicillin</a>, with some activity against <a href="../../../c/a/r/Carbenicillin.html" title="Carbenicillin">carbenicillin</a>; these enzymes are poorly inhibited by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a>, and some of them are ESBLs</p>
<p>the correct term is "OXACILLINASE". These enzymes are able to inactivate the oxazolylpenicillins like oxacilli, cloxacilli, dicloxacillin. The enzymes belong to the molecular class D not molecular class A.</p>
<p><a name="GROUP_2e:_CEPHALOSPORINASE.2C_Molecular_Class_A" id="GROUP_2e:_CEPHALOSPORINASE.2C_Molecular_Class_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2e: CEPHALOSPORINASE, Molecular Class A">edit</a>]</span> <span class="mw-headline">GROUP 2e: CEPHALOSPORINASE, Molecular Class A</span></h5>
<p><i>Subgroup 2e</i> enzymes are cephalosporinases that can also hydrolyse <a href="../../../m/o/n/Monobactams.html" title="Monobactams">monobactams</a>, and they are inhibited by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a></p>
<p><a name="GROUP_2f:_CARBAPENAMASE.2C_Molecular_Class_A" id="GROUP_2f:_CARBAPENAMASE.2C_Molecular_Class_A"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 2f: CARBAPENAMASE, Molecular Class A">edit</a>]</span> <span class="mw-headline">GROUP 2f: CARBAPENAMASE, Molecular Class A</span></h5>
<p><i>Subgroup 2f</i> was added because these are <a href="../../../s/e/r/Serine.html" title="Serine">serine</a> based carbapenemases, in contrast to the zinc based carbapenemases included in group 3</p>
<p><a name="Group_3" id="Group_3"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Group 3">edit</a>]</span> <span class="mw-headline">Group 3</span></h4>
<p><a name="GROUP_3:_METALLOENZYME.2C_Molecular_Class_B_.28not_inhibited_by_clavulanic_acid.29" id="GROUP_3:_METALLOENZYME.2C_Molecular_Class_B_.28not_inhibited_by_clavulanic_acid.29"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 3: METALLOENZYME, Molecular Class B (not inhibited by clavulanic acid)">edit</a>]</span> <span class="mw-headline">GROUP 3: METALLOENZYME, Molecular Class B <i>(not inhibited by clavulanic acid)</i></span></h5>
<p>Group 3 are the <a href="../../../z/i/n/Zinc.html" title="Zinc">zinc</a> based or metallo {beta} lactamases, corresponding to the molecular class B, which are the only enzymes acting by the metal ion zinc as discussed above. They are able to hydrolyse penicillins, cephalosporins, and carbapenems. Thus, carbapenems are inhibited by both group 2f (serine based mechanism) and group 3 (zinc based mechanism)</p>
<p><a name="Group_4" id="Group_4"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Group 4">edit</a>]</span> <span class="mw-headline">Group 4</span></h4>
<p><a name="GROUP_4:_PENICILLINASE.2C_No_Molecular_Class_.28not_inhibited_by_clavulanic_acid.29" id="GROUP_4:_PENICILLINASE.2C_No_Molecular_Class_.28not_inhibited_by_clavulanic_acid.29"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: GROUP 4: PENICILLINASE, No Molecular Class (not inhibited by clavulanic acid)">edit</a>]</span> <span class="mw-headline">GROUP 4: PENICILLINASE, No Molecular Class <i>(not inhibited by clavulanic acid)</i></span></h5>
<p>Group 4 are penicillinases that are not inhibited by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a>, and they do not yet have a corresponding molecular class.</p>
<p><a name="Molecular_Classification" id="Molecular_Classification"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Molecular Classification">edit</a>]</span> <span class="mw-headline">Molecular Classification</span></h3>
<p>The molecular classification of {beta} lactamases is based on the nucleotide and amino acid sequences in these enzymes. To date, four classes are recognised (A-D), correlating with the functional classification . Classes A, C, and D act by a <a href="../../../s/e/r/Serine.html" title="Serine">serine</a> based mechanism, whereas class B or metallo {beta} lactamases need <a href="../../../z/i/n/Zinc.html" title="Zinc">zinc</a> for their action<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[3]</a></sup></p>
<p>"Penicillinase" was discovered in 1940 and re-named Beta-lactamase when the structure of the Beta-lactam ring was finally elucidated.</p>
<p><a name="Resistance_in_gram_negative_bacteria" id="Resistance_in_gram_negative_bacteria"></a></p>
<h2><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Resistance in gram negative bacteria">edit</a>]</span> <span class="mw-headline">Resistance in gram negative bacteria</span></h2>
<p>Among gram-negative bacteria, the emergence of resistance to expanded-spectrum cephalosporins has been a major concern. It appeared initially in a limited number of bacterial species (<i>E. cloacae</i> , <i>C. freundii</i>, <i><a href="../../../s/2E/_/S._marcescens.html" title="S. marcescens">S. marcescens</a></i>, and <i><a href="../../../p/2E/_/P._aeruginosa.html" title="P. aeruginosa">P. aeruginosa</a></i> ) that could mutate to hyperproduce their chromosomal class C Î²-lactamase. A few years later, resistance appeared in bacterial species not naturally producing AmpC enzymes (<i><a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a></i>, <i><a href="../../../s/a/l/Salmonella.html" title="Salmonella">Salmonella</a></i> spp., <i><a href="../../../p/2E/_/P._mirabilis.html" title="P. mirabilis">P. mirabilis</a></i>) due to the production of TEM- or SHV-type ESBLs. Characteristically, such resistance has included oxyimino- (for example ceftizoxime, <a href="../../../c/e/f/Cefotaxime.html" title="Cefotaxime">cefotaxime</a> , <a href="../../../c/e/f/Ceftriaxone.html" title="Ceftriaxone">ceftriaxone</a>, and <a href="../../../c/e/f/Ceftazidime.html" title="Ceftazidime">ceftazidime</a>, as well as the oxyimino-monobactam <a href="../../../a/z/t/Aztreonam.html" title="Aztreonam">aztreonam</a> )but not 7-alpha-methoxy-cephalosporins (<a href="../../../c/e/p/Cephamycins.html" title="Cephamycins">cephamycins</a>) or in other words (cefoxitin and <a href="../../../c/e/f/Cefotetan.html" title="Cefotetan">cefotetan</a> ), has been blocked by inhibitors such as <a href="../../../c/l/a/Clavulanate.html" title="Clavulanate">clavulanate</a>, <a href="../../../s/u/l/Sulbactam.html" title="Sulbactam">sulbactam</a>, or <a href="../../../t/a/z/Tazobactam.html" title="Tazobactam">tazobactam</a>, and did not involve <a href="../../../c/a/r/Carbapenems.html" title="Carbapenems">carbapenems</a>. Plasmid-mediated AmpC Î²-lactamases represent a new threat since they confer resistance to 7-alpha-methoxy-cephalosporins (<a href="../../../c/e/p/Cephamycins.html" title="Cephamycins">cephamycins</a>) such as cefoxitin or <a href="../../../c/e/f/Cefotetan.html" title="Cefotetan">cefotetan</a>, are not affected by commercially available Î²-lactamase inhibitors, and can, in strains with loss of outer membrane porins, provide resistance to carbapenems.<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[4]</a></sup> . <a name="Extended_spectrum_beta_lactamase_.28ESBL.29" id="Extended_spectrum_beta_lactamase_.28ESBL.29"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Extended spectrum beta lactamase (ESBL)">edit</a>]</span> <span class="mw-headline">Extended spectrum beta lactamase (ESBL)</span></h3>
<p>Members of the family <a href="../../../e/n/t/Enterobacteriaceae.html" title="Enterobacteriaceae">Enterobacteriaceae</a> commonly express plasmid-encoded Î²-lactamases (e.g., TEM-1, TEM-2, and SHV-1) which confer resistance to penicillins but not to expanded-spectrum cephalosporins . In the mid-1980s a new group of enzymes, the extended-spectrum b-lactamases (ESBLs), was detected. (first detected in Germany in 1983)<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[5]</a></sup>. ESBLs are beta-lactamases that hydrolyze extended-spectrum cephalosporins with an oxyimino side chain. These cephalosporins include <a href="../../../c/e/f/Cefotaxime.html" title="Cefotaxime">cefotaxime</a>, <a href="../../../c/e/f/Ceftriaxone.html" title="Ceftriaxone">ceftriaxone</a>, and <a href="../../../c/e/f/Ceftazidime.html" title="Ceftazidime">ceftazidime</a>, as well as the oxyimino-monobactam <a href="../../../a/z/t/Aztreonam.html" title="Aztreonam">aztreonam</a>. ESBLs confer resistance to expanded-spectrum cephalosporins (e.g. <a href="../../../c/e/f/Ceftriaxone.html" title="Ceftriaxone">ceftriaxone</a>, <a href="../../../c/e/f/Cefotaxime.html" title="Cefotaxime">cefotaxime</a>,and <a href="../../../c/e/f/Ceftazidime.html" title="Ceftazidime">ceftazidime</a> ), <a href="../../../a/z/t/Aztreonam.html" title="Aztreonam">aztreonam</a>, and related oxyimino-beta lactams. Typically, they derive from genes for TEM-1, TEM-2, or SHV-1 by mutations that alter the amino acid configuration around the active site of these Ã-lactamases. This extends the spectrum of Ã-lactam antibiotics susceptible to hydrolysis by these enzymes. An increasing number of ESBLs not of TEM or SHV lineage have recently been described.<sup id="_ref-5" class="reference"><a href="#_note-5" title="">[6]</a></sup> . The ESBLs are frequently plasmid encoded. Plasmids responsible for ESBL production frequently carry genes encoding resistance to other drug classes (for example, aminoglycosides). Therefore, antibiotic options in the treatment of ESBL-producing organisms are extremely limited. Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported. ESBL-producing organisms may appear susceptible to some extended-spectrum cephalosporins. However, treatment with such antibiotics has been associated with high failure rates. <a name="Types" id="Types"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Types">edit</a>]</span> <span class="mw-headline">Types</span></h4>
<p><sup id="_ref-6" class="reference"><a href="#_note-6" title="">[7]</a></sup><sup id="_ref-7" class="reference"><a href="#_note-7" title="">[8]</a></sup> <a name="TEM_beta-lactamases_.28class_A.29" id="TEM_beta-lactamases_.28class_A.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: TEM beta-lactamases (class A)">edit</a>]</span> <span class="mw-headline">TEM beta-lactamases (class A)</span></h4>
<p>TEM-1 is the most commonly encountered beta-lactamase in <a href="../../../g/r/a/Gram-negative.html" title="Gram-negative">gram-negative</a> bacteria. Up to 90% of ampicillin resistance in <a href="../../../e/2E/_/E._coli.html" title="E. coli">E. coli</a> is due to the production of TEM-1. Also responsible for the ampicillin and penicillin resistance that is seen in <i><a href="../../../h/2E/_/H._influenzae.html" title="H. influenzae">H. influenzae</a></i> and <i><a href="../../../n/2E/_/N._gonorrhoeae.html" title="N. gonorrhoeae">N. gonorrhoeae</a></i> in increasing numbers. Although TEM-type beta-lactamases are most often found in <i><a href="../../../e/2E/_/E._coli.html" title="E. coli">E. coli</a></i> and <i><a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a></i>, they are also found in other species of gram-negative bacteria with increasing frequency. The amino acid substitutions responsible for the ESBL phenotype cluster around the active site of the enzyme and change its configuration, allowing access to oxyimino-beta-lactam substrates. Opening the active site to</p>
<p>b-lactam substrates also typically enhances the susceptibility of the enzyme to b-lactamase inhibitors, such as clavulanic acid. Single amino acid substitutions at positions 104, 164, 238, and 240 produce the ESBL phenotype, but ESBLs with the broadest spectrum usually have more than a single amino acid substitution. Based upon different combinations of changes, currently 140 TEM-type enzymes have been described. TEM-10, TEM-12, and TEM-26 are among the most common in the United States.<sup id="_ref-8" class="reference"><a href="#_note-8" title="">[9]</a></sup> <a name="SHV_beta-lactamases_.28class_A.29" id="SHV_beta-lactamases_.28class_A.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: SHV beta-lactamases (class A)">edit</a>]</span> <span class="mw-headline">SHV beta-lactamases (class A)</span></h4>
<p>SHV-1 shares 68 percent of its amino acids with TEM-1 and has a similar overall structure. The SHV-1 beta-lactamase is most commonly found in <i><a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a></i> and is responsible for up to 20% of the plasmid-mediated ampicillin resistance in this species. ESBLs in this family also have amino acid changes around the active site, most commonly at positions 238 or 238 and 240. More than 60 SHV varieties are known. They are the predominant ESBL type in Europe and the United States and are found worldwide. SHV-5 and SHV-12 are among the most common.<sup id="_ref-9" class="reference"><a href="#_note-9" title="">[10]</a></sup> <a name="CTX-M_beta-lactamases_.28class_A.29" id="CTX-M_beta-lactamases_.28class_A.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: CTX-M beta-lactamases (class A)">edit</a>]</span> <span class="mw-headline">CTX-M beta-lactamases (class A)</span></h4>
<p>These enzymes were named for their greater activity against <a href="../../../c/e/f/Cefotaxime.html" title="Cefotaxime">cefotaxime</a> than other oxyimino-beta-lactam substrates (eg, <a href="../../../c/e/f/Ceftazidime.html" title="Ceftazidime">ceftazidime</a>, <a href="../../../c/e/f/Ceftriaxone.html" title="Ceftriaxone">ceftriaxone</a>, or <a href="../../../c/e/f/Cefepime.html" title="Cefepime">cefepime</a>). Rather than arising by mutation, they represent examples of plasmid acquisition of beta-lactamase genes normally found on the chromosome of <i>Kluyvera</i> species, a group of rarely pathogenic commensal organisms. These enzymes are not very closely related to TEM or SHV beta-lactamases in that they show only approximately 40% identity with these two commonly isolated beta-lactamases. More than 40 CTX-M enzymes are currently known. Despite their name, a few are more active on <a href="../../../c/e/f/Ceftazidime.html" title="Ceftazidime">ceftazidime</a> than <a href="../../../c/e/f/Cefotaxime.html" title="Cefotaxime">cefotaxime</a>. They have mainly been found in strains of <i><a href="../../../s/a/l/Salmonella_enterica.html" title="Salmonella enterica">Salmonella enterica</a></i> serovar <i>Typhimurium</i> and <i><a href="../../../e/2E/_/E._coli.html" title="E. coli">E. coli</a></i>, but have also been described in other species of <a href="../../../e/n/t/Enterobacteriaceae.html" title="Enterobacteriaceae">Enterobacteriaceae</a> and are the predominant ESBL type in parts of South America. (They are also seen in eastern Europe) CTX-M-14, CTX-M-3, and CTX-M-2 are the most widespread. CTX-M-15 is currently (2006) the most widespread type in <i><a href="../../../e/s/c/Escherichia_coli.html" title="Escherichia coli">E. coli</a></i> the UK and is widely prevalent in the community.<sup id="_ref-10" class="reference"><a href="#_note-10" title="">[11]</a></sup></p>
<p><a name="OXA_beta-lactamases_.28class_D.29" id="OXA_beta-lactamases_.28class_D.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: OXA beta-lactamases (class D)">edit</a>]</span> <span class="mw-headline">OXA beta-lactamases (class D)</span></h4>
<p>OXA beta-lactamases were long recognized as a less common but also plasmid-mediated beta-lactamase variety that could hydrolyze <a href="../../../o/x/a/Oxacillin.html" title="Oxacillin">oxacillin</a> and related anti-staphylococcal penicillins. These beta-lactamases differ from the TEM and SHV enzymes in that they belong to molecular class D and functional group 2d . The OXA-type beta-lactamases confer resistance to <a href="../../../a/m/p/Ampicillin.html" title="Ampicillin">ampicillin</a> and <a href="../../../c/e/p/Cephalothin.html" title="Cephalothin">cephalothin</a> and are characterized by their high hydrolytic activity against <a href="../../../o/x/a/Oxacillin.html" title="Oxacillin">oxacillin</a> and <a href="../../../c/l/o/Cloxacillin.html" title="Cloxacillin">cloxacillin</a> and the fact that they are poorly inhibited by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a>. Amino acid substitutions in OXA enzymes can also give the ESBL phenotype. While most ESBLs have been found in <i><a href="../../../e/2E/_/E._coli.html" title="E. coli">E. coli</a></i>, <i><a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a></i>, and other <a href="../../../e/n/t/Enterobacteriaceae.html" title="Enterobacteriaceae">Enterobacteriaceae</a>, the OXA-type ESBLs have been found mainly in <i><a href="../../../p/2E/_/P._aeruginosa.html" title="P. aeruginosa">P. aeruginosa</a></i>. OXA-type ESBLs have been found mainly in <i><a href="../../../p/s/e/Pseudomonas_aeruginosa.html" title="Pseudomonas aeruginosa">Pseudomonas aeruginosa</a></i> isolates from Turkey and France. The OXA beta-lactamase family was originally created as a phenotypic rather than a genotypic group for a few beta-lactamases that had a specific hydrolysis profile. Therefore, there is as little as 20% sequence homology among some of the members of this family. However, recent additions to this family show some degree of homology to one or more of the existing members of the OXA beta-lactamase family. Some confer resistance predominantly to ceftazidime, but OXA-17 confers greater resistance to cefotaxime and cefepime than it does resistance to ceftazidime.</p>
<p><a name="Others" id="Others"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Others">edit</a>]</span> <span class="mw-headline">Others</span></h4>
<p>Other plasmid-mediated ESBLs, such as PER, VEB, GES, and IBC beta-lactamases, have been described but are uncommon and have been found mainly in <i><a href="../../../p/2E/_/P._aeruginosa.html" title="P. aeruginosa">P. aeruginosa</a></i> and at a limited number of geographic sites. PER-1 in isolates in Turkey, France, and Italy; VEB-1 and VEB-2 in strains from Southeast Asia; and GES-1, GES-2, and IBC-2 in isolates from South Africa, France, and Greece. PER-1 is also common in multiresistant acinetobacter species in Korea and Turkey. Some of these enzymes are found in Enterobacteriaceae as well, whereas other uncommon ESBLs (such as BES-1, IBC-1, SFO-1, and TLA-1) have been found only in Enterobacteriaceae.</p>
<p><a name="Treatment" id="Treatment"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Treatment">edit</a>]</span> <span class="mw-headline">Treatment</span></h4>
<p>While ESBL-producing organisms were previously associated with hospitals and institutional care, these organisms are now increasingly found in the community. CTM-15 positive <a href="../../../e/s/c/Escherichia_coli.html" title="Escherichia coli">E. coli</a> are a cause of community-acquired <a href="../../../c/y/s/Cystitis.html" title="Cystitis">urinary infections</a> in the UK,<sup id="_ref-11" class="reference"><a href="#_note-11" title="">[12]</a></sup> and tend to be resistant to all oral Î²-lactam antibiotics, as well as <a href="../../../q/u/i/Quinolones.html" title="Quinolones">quinolones</a> and <a href="../../../s/u/l/Sulphonamide.html" title="Sulphonamide">sulphonamides</a>. Treatment options may include <a href="../../../n/i/t/Nitrofurantoin.html" title="Nitrofurantoin">nitrofurantoin</a>, fosfomycin, mecillinam and <a href="../../../c/h/l/Chloramphenicol.html" title="Chloramphenicol">chloramphenicol</a>. In desperation, once-daily <a href="../../../e/r/t/Ertapenem.html" title="Ertapenem">ertapenem</a> or <a href="../../../g/e/n/Gentamicin.html" title="Gentamicin">gentamicin</a> injections may also be used.</p>
<p><a name="INHIBITOR_RESISTANT_.CE.B2-LACTAMASES" id="INHIBITOR_RESISTANT_.CE.B2-LACTAMASES"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: INHIBITOR RESISTANT Î²-LACTAMASES">edit</a>]</span> <span class="mw-headline">INHIBITOR RESISTANT Î²-LACTAMASES</span></h3>
<p>Although the inhibitor-resistant Î²-lactamases are not ESBLs, they are often discussed with ESBLs because they are also derivatives of the classical TEM- or SHV-type enzymes. These enzymes were at first given the designation IRT for inhibitor-resistant TEM Î²-lactamase; however, all have subsequently been renamed with numerical TEM designations. There are at least 19 distinct inhibitor-resistant TEM Î²-lactamases. Inhibitor-resistant TEM Î²-lactamases have been found mainly in clinical isolates of <i><a href="../../../e/2E/_/E._coli.html" title="E. coli">E. coli</a></i>, but also some strains of <i><a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a></i>, <i><a href="../../../k/l/e/Klebsiella_oxytoca.html" title="Klebsiella oxytoca">Klebsiella oxytoca</a></i>, <i><a href="../../../p/2E/_/P._mirabilis.html" title="P. mirabilis">P. mirabilis</a></i>, and <i>Citrobacter freundii</i> .Although the inhibitor-resistant TEM variants are resistant to inhibition by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a> and <a href="../../../s/u/l/Sulbactam.html" title="Sulbactam">sulbactam</a>, thereby showing clinical resistance to the beta-lactam--lactamase inhibitor combinations of <a href="../../../a/m/o/Amoxicillin.html" title="Amoxicillin">amoxicillin</a>-<a href="../../../c/l/a/Clavulanate.html" title="Clavulanate">clavulanate</a> (<a href="../../../c/o/-/Co-amoxiclav.html" title="Co-amoxiclav">Co-amoxiclav</a>), <a href="../../../t/i/c/Ticarcillin.html" title="Ticarcillin">ticarcillin</a>-<a href="../../../c/l/a/Clavulanate.html" title="Clavulanate">clavulanate</a>, and <a href="../../../a/m/p/Ampicillin_sulbactam_21cb.html" title="Ampicillin/sulbactam">ampicillin/sulbactam</a>, they remain susceptible to inhibition by <a href="../../../t/a/z/Tazobactam.html" title="Tazobactam">tazobactam</a> and subsequently the combination of <a href="../../../p/i/p/Piperacillin_tazobactam_98ff.html" title="Piperacillin/tazobactam">piperacillin/tazobactam</a>. To date, these beta-lactamases have primarily been detected in France and a few other locations within Europe..<sup id="_ref-12" class="reference"><a href="#_note-12" title="">[13]</a></sup> <a name="AmpC_TYPE_.CE.B2-LACTAMASES_.28CLASS_C.29" id="AmpC_TYPE_.CE.B2-LACTAMASES_.28CLASS_C.29"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: AmpC TYPE Î²-LACTAMASES (CLASS C)">edit</a>]</span> <span class="mw-headline">AmpC TYPE Î²-LACTAMASES (CLASS C)</span></h3>
<p>AmpC type Î²-lactamases are commonly isolated from extended-spectrum cephalosporin-resistant Gram-negative bacteria. AmpC Î²-lactamases (also termed class C or group 1) are typically encoded on the chromosome of many Gram-negative bacteria including <i><a href="../../../c/i/t/Citrobacter.html" title="Citrobacter">Citrobacter</a></i>, <i><a href="../../../s/e/r/Serratia.html" title="Serratia">Serratia</a></i> and <i><a href="../../../e/n/t/Enterobacter.html" title="Enterobacter">Enterobacter</a></i> species where its expression is usually inducible; it may also occur on <i><a href="../../../e/s/c/Escherichia_coli.html" title="Escherichia coli">Escherichia coli</a></i> but is not usually inducible, although it can be hyperexpressed. AmpC type Î²-lactamases may also be carried on plasmids.<sup id="_ref-13" class="reference"><a href="#_note-13" title="">[14]</a></sup> AmpC Î²-lactamases, in contrast to ESBLs, hydrolyse broad and extended-spectrum cephalosporins (cephamycins as well as to oxyimino-Î²-lactams) but are not inhibited by Î²-lactamase inhibitors such as <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a>.</p>
<p><a name="CARBAPENEMASES" id="CARBAPENEMASES"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: CARBAPENEMASES">edit</a>]</span> <span class="mw-headline">CARBAPENEMASES</span></h3>
<p>Carbapenems are famously stable to AmpC Î²-lactamases and extended-spectrum-Î²-lactamases. Carbapenemases are a diverse group of b-lactamases that are active not only against the oxyimino-cephalosporins and cephamycins but also against the carbapenems. Aztreonam is stable to the metallo-Î²-lactamases but many IMP and VIM producers are resistant, owing to other mechanisms. Carbapenemases were formerly believed to derive only from classes A, B, and D, but a class C carbapenemase has been described.</p>
<p><a name="IMP-type_carbapenemases_.28one_of_the_metallo-b-lactamases.29" id="IMP-type_carbapenemases_.28one_of_the_metallo-b-lactamases.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: IMP-type carbapenemases (one of the metallo-b-lactamases)">edit</a>]</span> <span class="mw-headline">IMP-type carbapenemases (one of the metallo-b-lactamases)</span></h4>
<p>Plasmidmediated IMP-type carbapenemases, 17 varieties of which are currently known, became established in Japan in the 1990s in both enteric gram-negative organisms and in pseudomonas and acinetobacter species. IMP enzymes spread slowly to other countries in the Far East, were reported from Europe in 1997, and have been found in Canada and Brazil.</p>
<p><a name="VIM_.28Verona_integron-encoded_metallo-b-lactamase.29" id="VIM_.28Verona_integron-encoded_metallo-b-lactamase.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: VIM (Verona integron-encoded metallo-b-lactamase)">edit</a>]</span> <span class="mw-headline">VIM (Verona integron-encoded metallo-b-lactamase)</span></h4>
<p>A second growing family of carbapenemases, the VIM family, was reported from Italy in 1999 and now includes 10 members, which have a wide geographic distribution in Europe, South America, and the Far East and have been found in the United States. VIM-1 was discovered in P. aeruginosa in Italy in 1996; subsequently, VIM-2 -now the predominant variant- was found repeatedly in Europe and the Far East; VIM-3 and -4 are minor variants of VIM-2 and -1, respectively. VIM enzymes mostly occur in P. aeruginosa, also P. putidaand, very rarely, Enterobacteriaceae</p>
<p>Amino acid sequence diversity is up to 10% in the VIM family, 15% in the IMP family, and 70% between VIM and IMP. Enzymes of both the families nevertheless are similar.1 Both are integron-associated, sometimes within plasmids. Both hydrolyse all Î²-lactams except monobactams, and evade all Î²-lactam inhibitors.</p>
<p><a name="OXA_.28oxacillinase.29_group_of_.CE.B2-lactamases_.28Class_D.29" id="OXA_.28oxacillinase.29_group_of_.CE.B2-lactamases_.28Class_D.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: OXA (oxacillinase) group of Î²-lactamases (Class D)">edit</a>]</span> <span class="mw-headline">OXA (oxacillinase) group of Î²-lactamases (Class D)</span></h4>
<p>The OXA group of Î²-lactamases mainly occur in Acinetobacter species and are divided into two clusters. OXA carbapenemases hydrolyse carbapenems very slowly <i>in vitro</i>, and the high MICs seen for some Acinetobacter hosts (&gt;64 mg/L) may reflect secondary mechanisms. They are sometimes augmented in clinical isolates by additional resistance mechanisms, such as impermeability or efflux.</p>
<p><a name="KPC_.28K._pneumoniae_carbapenemase.29_.28Class_A.29" id="KPC_.28K._pneumoniae_carbapenemase.29_.28Class_A.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: KPC (K. pneumoniae carbapenemase) (Class A)">edit</a>]</span> <span class="mw-headline">KPC (K. pneumoniae carbapenemase) (Class A)</span></h4>
<p>A few class A enzymes, notably the plasmid-mediated KPC enzymes, are effective carbapenemases as well. Three variants are known, distinguished by one or two amino-acid substitutions. KPC-1 was found in North Carolina, KPC-2 in Baltimore and KPC-3 in New York. They have only 45% homology with SME and NMC/IMI enzymes and, unlike them, can be encoded by self-transmissible plasmids.</p>
<p><a name="CMY_.28Class_C.29" id="CMY_.28Class_C.29"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: CMY (Class C)">edit</a>]</span> <span class="mw-headline">CMY (Class C)</span></h4>
<p>The first class C carbapenemase was described in 2006 and was isolated from a virulent strain of <i>Enterobacter aerogenes</i>.<sup id="_ref-14" class="reference"><a href="#_note-14" title="">[15]</a></sup> It is carried on a plasmid, pYMG-1, and is therefore transmissible to other bacterial strains.<sup id="_ref-15" class="reference"><a href="#_note-15" title="">[16]</a></sup></p>
<p><a name="SME.2C_IMI.2C_NMC_and_CcrA" id="SME.2C_IMI.2C_NMC_and_CcrA"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: SME, IMI, NMC and CcrA">edit</a>]</span> <span class="mw-headline">SME, IMI, NMC and CcrA</span></h4>
<p>generally of little clinical significance.</p>
<p>CcrA (CfiA). Its gene occurs in c. 1-3% of B. fragilis isolates, but fewer produce the enzyme since expression demands appropriate migration of an insertion sequence. CcrA was known before imipenem was introduced, and producers have shown little subsequent increase.</p>
<p><a name="Treatment_of_ESBL.2FAmpC.2Fcarbapenemases" id="Treatment_of_ESBL.2FAmpC.2Fcarbapenemases"></a></p>
<h2><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Treatment of ESBL/AmpC/carbapenemases">edit</a>]</span> <span class="mw-headline"><b>Treatment of ESBL/AmpC/carbapenemases</b></span></h2>
<p><a name="General_Overview" id="General_Overview"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: General Overview">edit</a>]</span> <span class="mw-headline">General Overview</span></h4>
<p>Generally, an isolate is suspected to be an ESBL producer when it shows <i>in vitro</i> susceptibility to the second generation cephalosporins (cefoxitin, cefotetan) but resistance to the third generation cephalosporins and to aztreonam. Moreover, one should suspect these strains when treatment with these agents for Gram negative infections fails despite reported <i>in vitro</i> susceptibility. Once an ESBL producing strain is detected, the laboratory should report it as âresistantâ to all penicillins, cephalosporins, and aztreonam, even if they test as susceptible. Associated resistance to <a href="../../../a/m/i/Aminoglycosides.html" title="Aminoglycosides">aminoglycosides</a> and <a href="../../../t/r/i/Trimethoprim.html" title="Trimethoprim">trimethoprim</a>-<a href="../../../s/u/l/Sulfamethoxazole.html" title="Sulfamethoxazole">sulfamethoxazole</a> as well as high frequency of co-existence of <a href="../../../f/l/u/Fluoroquinolone.html" title="Fluoroquinolone">fluoroquinolone</a> resistance creates problems. Beta-lactamase inhibitors such as <a href="../../../c/l/a/Clavulanate.html" title="Clavulanate">clavulanate</a>, <a href="../../../s/u/l/Sulbactam.html" title="Sulbactam">sulbactam</a> or <a href="../../../t/a/z/Tazobactam.html" title="Tazobactam">tazobactam</a> <i>in vitro</i> inhibit most ESBLs, but the clinical effectiveness of beta-lactam/beta-lactamase inhibitor combinations cannot be relied on consistently for therapy. Although <a href="../../../c/e/p/Cephamycins.html" title="Cephamycins">cephamycins</a> (cefoxitin and <a href="../../../c/e/f/Cefotetan.html" title="Cefotetan">cefotetan</a>) are not hydrolyzed by majority of ESBLs but are hydrolyzed by associated AmpC-type Ã-lactamase. similarly Ã-lactam/Ã-lactamase inhibitor combinations may not be effective against organisms that produce AmpC-type Ã-lactamase. Also sometimes these strains decrease the expression of outer membrane proteins, rendering them resistant to cephamycins. <i>In vivo</i> studies have yielded mixed results against ESBL-producing <i><a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a></i>. (<a href="../../../c/e/f/Cefepime.html" title="Cefepime">Cefepime</a>, a fourth-generation cephalosporin, has demonstrated <i>in vitro</i> stability in the presence of many ESBL/AmpC strains.) Currently, <a href="../../../c/a/r/Carbapenems.html" title="Carbapenems">carbapenems</a> are generally regarded as the preferred agent for treatment of infections due to ESBL-producing organisms. Carbapenems are resistant to ESBL-mediated hydrolysis and exhibit excellent <i>in vitro</i> activity against strains of <a href="../../../e/n/t/Enterobacteriaceae.html" title="Enterobacteriaceae">Enterobacteriaceae</a> expressing ESBLs.</p>
<p><a name="According_to_genes" id="According_to_genes"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: According to genes">edit</a>]</span> <span class="mw-headline">According to genes</span></h4>
<p><a name="ESBLs" id="ESBLs"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: ESBLs">edit</a>]</span> <span class="mw-headline">ESBLs</span></h5>
<p>Strains producing only ESBLs are susceptible to <a href="../../../c/e/p/Cephamycins.html" title="Cephamycins">cephamycins</a> and <a href="../../../c/a/r/Carbapenems.html" title="Carbapenems">carbapenems</a> <i>in vitro</i> and show little if any inoculum effect with these agents.</p>
<p>For organisms producing <b>TEM</b> and <b>SHV</b> type ESBLs, apparent <i>in vitro</i> sensitivity to <a href="../../../c/e/f/Cefepime.html" title="Cefepime">cefepime</a> and to <a href="../../../p/i/p/Piperacillin_tazobactam_98ff.html" title="Piperacillin/tazobactam">piperacillin/tazobactam</a> is common, but both drugs show an inoculum effect, with diminished susceptibility as the size of the inoculum is increased from 100000 to 10000000 organisms.</p>
<p>Strains with some <b>CTX-M</b>âtype and <b>OXA</b>-type ESBLs are resistant to <a href="../../../c/e/f/Cefepime.html" title="Cefepime">cefepime</a> on testing, despite the use of a standard inoculum.</p>
<p><a name="Inhibitor-Resistant_.CE.B2-Lactamases" id="Inhibitor-Resistant_.CE.B2-Lactamases"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: Inhibitor-Resistant Î²-Lactamases">edit</a>]</span> <span class="mw-headline">Inhibitor-Resistant Î²-Lactamases</span></h5>
<p>Although the inhibitor-resistant TEM variants are resistant to inhibition by <a href="../../../c/l/a/Clavulanic_acid.html" title="Clavulanic acid">clavulanic acid</a> and <a href="../../../s/u/l/Sulbactam.html" title="Sulbactam">sulbactam</a>, thereby showing clinical resistance to the beta-lactam--lactamase inhibitor combinations of <a href="../../../a/m/o/Amoxicillin.html" title="Amoxicillin">amoxicillin</a>-<a href="../../../c/l/a/Clavulanate.html" title="Clavulanate">clavulanate</a> (<a href="../../../c/o/-/Co-amoxiclav.html" title="Co-amoxiclav">Co-amoxiclav</a>), <a href="../../../t/i/c/Ticarcillin.html" title="Ticarcillin">ticarcillin</a>-<a href="../../../c/l/a/Clavulanate.html" title="Clavulanate">clavulanate</a>, and <a href="../../../a/m/p/Ampicillin_sulbactam_21cb.html" title="Ampicillin/sulbactam">ampicillin/sulbactam</a>, they remain susceptible to inhibition by <a href="../../../t/a/z/Tazobactam.html" title="Tazobactam">tazobactam</a> and subsequently the combination of <a href="../../../p/i/p/Piperacillin_tazobactam_98ff.html" title="Piperacillin/tazobactam">piperacillin/tazobactam</a>.</p>
<p><a name="AmpC" id="AmpC"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: AmpC">edit</a>]</span> <span class="mw-headline">AmpC</span></h5>
<p>AmpC-producing strains are typically resistant to oxyimino-beta lactams and to <a href="../../../c/e/p/Cephamycins.html" title="Cephamycins">cephamycins</a> and are susceptible to <a href="../../../c/a/r/Carbapenems.html" title="Carbapenems">carbapenems</a>; however, diminished porin expression can make such a strain carbapenem-resistant as well.</p>
<p><a name="carbapenemases" id="carbapenemases"></a></p>
<h5><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: carbapenemases">edit</a>]</span> <span class="mw-headline">carbapenemases</span></h5>
<p>Strains with <b>IMP-, VIM-, and OXA</b>-type carbapenemases usually remain susceptible to <a href="../../../a/z/t/Aztreonam.html" title="Aztreonam">aztreonam</a>. Resistance to nonâb-lactam antibiotics is common in strains making any of these enzymes, such that alternative options for nonâb-lactam therapy need to be determined by direct susceptibility testing. Resistance to <a href="../../../f/l/u/Fluoroquinolones.html" title="Fluoroquinolones">fluoroquinolones</a> and <a href="../../../a/m/i/Aminoglycosides.html" title="Aminoglycosides">aminoglycosides</a> is especially high.</p>
<p><a name="According_to_Species" id="According_to_Species"></a></p>
<h3><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: According to Species">edit</a>]</span> <span class="mw-headline">According to Species</span></h3>
<p><a name="E._coli_or_klebsiella" id="E._coli_or_klebsiella"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: E. coli or klebsiella">edit</a>]</span> <span class="mw-headline">E. coli or klebsiella</span></h4>
<p>For infections caused by ESBL-producing <a href="../../../e/2E/_/E._coli.html" title="E. coli">E. coli</a> or <a href="../../../k/l/e/Klebsiella.html" title="Klebsiella">klebsiella</a> species, treatment with <a href="../../../i/m/i/Imipenem.html" title="Imipenem">imipenem</a> or <a href="../../../m/e/r/Meropenem.html" title="Meropenem">meropenem</a> has been associated with the best outcomes in terms of survival and bacteriologic clearance. <a href="../../../c/e/f/Cefepime.html" title="Cefepime">Cefepime</a> and <a href="../../../p/i/p/Piperacillin_tazobactam_98ff.html" title="Piperacillin/tazobactam">piperacillin/tazobactam</a> have been less successful. <a href="../../../c/e/f/Ceftriaxone.html" title="Ceftriaxone">Ceftriaxone</a>, <a href="../../../c/e/f/Cefotaxime.html" title="Cefotaxime">cefotaxime</a>, and <a href="../../../c/e/f/Ceftazidime.html" title="Ceftazidime">ceftazidime</a> have failed even more often, despite the organismâs susceptibility to the antibiotic <i>in vitro</i>. Several reports have documented failure of <a href="../../../c/e/p/Cephamycin.html" title="Cephamycin">cephamycin</a> therapy as a result of resistance due to porin loss. Some patients have responded to <a href="../../../a/m/i/Aminoglycoside.html" title="Aminoglycoside">aminoglycoside</a> or <a href="../../../q/u/i/Quinolone.html" title="Quinolone">quinolone</a> therapy, but in a recent comparison of <a href="../../../c/i/p/Ciprofloxacin.html" title="Ciprofloxacin">ciprofloxacin</a> and <a href="../../../i/m/i/Imipenem.html" title="Imipenem">imipenem</a> for bacteremia involving an ESBL-producing <a href="../../../k/2E/_/K._pneumoniae.html" title="K. pneumoniae">K. pneumoniae</a>, <a href="../../../i/m/i/Imipenem.html" title="Imipenem">imipenem</a> produced the better outcome.</p>
<p><a name="P._aeruginosa" id="P._aeruginosa"></a></p>
<h4><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: P. aeruginosa">edit</a>]</span> <span class="mw-headline">P. aeruginosa</span></h4>
<p>There have been few clinical studies to define the optimal therapy for infections caused by ESBL producing <a href="../../../p/2E/_/P._aeruginosa.html" title="P. aeruginosa">P. aeruginosa</a> strains.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-2column">
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite style="font-style:normal">Abraham EP, Chain E (1940). "An enzyme from bacteria able to destroy penicillin". <i>Nature</i> <b>46</b>: 837.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=An+enzyme+from+bacteria+able+to+destroy+penicillin&amp;rft.title=Nature&amp;rft.jtitle=Nature&amp;rft.date=1940&amp;rft.volume=46&amp;rft.au=Abraham+EP%2C+Chain+E&amp;rft.pages=837">&#160;</span></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> *Bush K, Jacoby GA, Medeiros AA.1995. <a href="http://aac.asm.org/cgi/reprint/39/6/1211?ijkey=c8e8586b43c1d0526d3f78dcfadea52ad10fb65d&amp;keytype2=tf_ipsecsha" class="external text" title="http://aac.asm.org/cgi/reprint/39/6/1211?ijkey=c8e8586b43c1d0526d3f78dcfadea52ad10fb65d&amp;keytype2=tf_ipsecsha" rel="nofollow">"A functional classification scheme for beta-lactamases and its correlation with molecular structure."</a> <i>Antimicrob Agents Chemother.</i>. 1995;39: 1211-33</li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> *Ambler RP.1980. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=6109327&amp;dopt=Abstract" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=6109327&amp;dopt=Abstract" rel="nofollow">"The structure of beta-lactamases."</a> <i>Philos Trans R Soc Lond B Biol Sci.</i>. 1980;289: 321-31</li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> *Philippon A, Arlet B, Jacoby GA.2002. <a href="http://aac.asm.org/cgi/reprint/46/1/1.pdf" class="external text" title="http://aac.asm.org/cgi/reprint/46/1/1.pdf" rel="nofollow">"Plasmid-determined AmpC-type Î²-lactamases"</a> <i>Antimicrob Agents Chemother.</i>. 2002; 46: 1-11</li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> *Knothe H, Shah P. Kremery V, et al 1983. <a href="http://www.springerlink.com/content/g4r4734xk8148r1u/" class="external text" title="http://www.springerlink.com/content/g4r4734xk8148r1u/" rel="nofollow">"Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and</a> <a href="../../../s/e/r/Serratia_marcescens.html" title="Serratia marcescens">Serratia marcescens</a>" <i>Infection</i>. 1983; 11: 315-7</li>
<li id="_note-5"><b><a href="#_ref-5" title="">^</a></b> *Emery, C. L., and L. A. Weymouth. 1997. <a href="http://jcm.asm.org/cgi/content/abstract/35/8/2061?ijkey=d2affb0b60c6a70b4b4f1324e5c76e4c2559e370&amp;keytype2=tf_ipsecsha" class="external text" title="http://jcm.asm.org/cgi/content/abstract/35/8/2061?ijkey=d2affb0b60c6a70b4b4f1324e5c76e4c2559e370&amp;keytype2=tf_ipsecsha" rel="nofollow">"Detection and clinical significance of extended-spectrum Ã-lactamases in a tertiary-care medical center"</a> <i>J. Clin. Microbiol.</i>. 35:2061-2067</li>
<li id="_note-6"><b><a href="#_ref-6" title="">^</a></b> *Bradford PA.2001. <a href="http://intl-cmr.asm.org/cgi/reprint/14/4/933" class="external text" title="http://intl-cmr.asm.org/cgi/reprint/14/4/933" rel="nofollow">"Extended-spectrum Î²-lactamases in the 21st century:characterization, epidemiology, and detection of this important resistance threat."</a> Clin Microbiol Rev.<i>. 2001; 48:933-51</i></li>
<li id="_note-7"><b><a href="#_ref-7" title="">^</a></b> *George A. Jacoby, M.D., and Luisa Silvia Munoz-Price, M.D..2005. <a href="http://content.nejm.org/cgi/reprint/352/4/380.pdf?ijkey=e86019f128eb29d6015410037f622e01e12cadec" class="external text" title="http://content.nejm.org/cgi/reprint/352/4/380.pdf?ijkey=e86019f128eb29d6015410037f622e01e12cadec" rel="nofollow">"mechanisms of disease: The New beta-Lactamases."</a> N Engl J Med.<i>. 2005;352:380-91.</i></li>
<li id="_note-8"><b><a href="#_ref-8" title="">^</a></b> *Paterson DL, Hujer KM, Hujer AM, <i>et al.</i>2003. [<a href="http://aac.asm.org/cgi/reprint/47/11/3554" class="external free" title="http://aac.asm.org/cgi/reprint/47/11/3554" rel="nofollow">http://aac.asm.org/cgi/reprint/47/11/3554</a> "Extended-spectrum b-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type b-lactamases."] Antimicrob Agents Chemother<i>. 2003;</i> 47:3554-60.</li>
<li id="_note-9"><b><a href="#_ref-9" title="">^</a></b> *Paterson DL, Hujer KM, Hujer AM, <i>et al.</i>2003. [<a href="http://aac.asm.org/cgi/reprint/47/11/3554" class="external free" title="http://aac.asm.org/cgi/reprint/47/11/3554" rel="nofollow">http://aac.asm.org/cgi/reprint/47/11/3554</a> "Extended-spectrum b-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type b-lactamases."] Antimicrob Agents Chemother<i>. 2003;</i> 47:3554-60.</li>
<li id="_note-10"><b><a href="#_ref-10" title="">^</a></b> Woodford N, Ward E, Kaufmann ME, <i>et al.</i>. <a href="http://www.hpa.org.uk/cfi/armrl/ARMRL_posters/Woodford%20ECCMID%202004%20poster.pdf" class="external text" title="http://www.hpa.org.uk/cfi/armrl/ARMRL_posters/Woodford%20ECCMID%202004%20poster.pdf" rel="nofollow">Molecular characterisation of <i>Escherichia coli</i> isolates producing CTX-M-15 extended-spectrum Î²-lactamase (ESBL) in the United Kingdom</a>. Health Protection Agency. Retrieved on <a href="../../../n/o/v/November_19.html" title="November 19">November 19</a>, <a href="../../../2/0/0/2006.html" title="2006">2006</a>.</li>
<li id="_note-11"><b><a href="#_ref-11" title="">^</a></b> Woodford N, Ward E, Kaufmann ME, <i>et al.</i>. <a href="http://www.hpa.org.uk/cfi/armrl/ARMRL_posters/Woodford%20ECCMID%202004%20poster.pdf" class="external text" title="http://www.hpa.org.uk/cfi/armrl/ARMRL_posters/Woodford%20ECCMID%202004%20poster.pdf" rel="nofollow">Molecular characterisation of <i>Escherichia coli</i> isolates producing CTX-M-15 extended-spectrum Î²lactamase (ESBL) in the United Kingdom</a>. Retrieved on <a href="../../../n/o/v/November_8.html" title="November 8">November 8</a>, <a href="../../../2/0/0/2006.html" title="2006">2006</a>.</li>
<li id="_note-12"><b><a href="#_ref-12" title="">^</a></b> *Bradford PA.2001. <a href="http://intl-cmr.asm.org/cgi/reprint/14/4/933" class="external text" title="http://intl-cmr.asm.org/cgi/reprint/14/4/933" rel="nofollow">"Extended-spectrum Î²-lactamases in the 21st century:characterization, epidemiology, and detection of this important resistance threat."</a> Clin Microbiol Rev.<i>. 2001; 48:933-51</i></li>
<li id="_note-13"><b><a href="#_ref-13" title="">^</a></b> *Philippon A, Arlet B, Jacoby GA.2002. <a href="http://aac.asm.org/cgi/reprint/46/1/1.pdf" class="external text" title="http://aac.asm.org/cgi/reprint/46/1/1.pdf" rel="nofollow">"Plasmid-determined AmpC-type Î²-lactamases"</a> <i>Antimicrob Agents Chemother.</i>. 2002; 46:</li>
<li id="_note-14"><b><a href="#_ref-14" title="">^</a></b> <cite style="font-style:normal">Kim JY, Jung HI, An YJ, <i>et al.</i> (2006). "Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase". <i>Mol Microbiol</i> <b>60</b>: 907â16.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Structural+basis+for+the+extended+substrate+spectrum+of+CMY-10%2C+a+plasmid-encoded+class+C+beta-lactamase&amp;rft.title=Mol+Microbiol&amp;rft.jtitle=Mol+Microbiol&amp;rft.date=2006&amp;rft.volume=60&amp;rft.au=Kim+JY%2C+Jung+HI%2C+An+YJ%2C+%27%27et+al.%27%27&amp;rft.pages=907%26ndash%3B16">&#160;</span></li>
<li id="_note-15"><b><a href="#_ref-15" title="">^</a></b> <cite style="font-style:normal">Lee JH, Jung HI, Jung JH, <i>et al.</i> (2004). "Dissemination of transferable AmpC-type Î²-lactamase (CMY-10) in a Korean hospital". <i>Microbiol Drug Resist</i> <b>10</b>: 224â30.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Dissemination+of+transferable+AmpC-type+%CE%B2-lactamase+%28CMY-10%29+in+a+Korean+hospital&amp;rft.title=Microbiol+Drug+Resist&amp;rft.jtitle=Microbiol+Drug+Resist&amp;rft.date=2004&amp;rft.volume=10&amp;rft.au=Lee+JH%2C+Jung+HI%2C+Jung+JH%2C+%27%27et+al.%27%27&amp;rft.pages=224%26ndash%3B30">&#160;</span></li>
</ol>
</div>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../b/e/t/Beta-lactamase.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../b/e/t/Category%7EBeta-lactamase_inhibitors_f6f0.html" title="Category:Beta-lactamase inhibitors">Beta-lactamase inhibitors</a></li>
</ul>
<div class="NavFrame" style="clear:both;">
<div class="NavHead" style="background:#e7dcc3;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../c/a/r/Template%7ECarbon-nitrogen_non-peptide_hydrolases_a9d1.html" title="Template:Carbon-nitrogen non-peptide hydrolases"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">â¢</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">â¢</span>&#160;<a href="http://en.wikipedia.org../../../c/a/r/Template%7ECarbon-nitrogen_non-peptide_hydrolases_a9d1.html" class="external text" title="http://en.wikipedia.org../../../c/a/r/Template%7ECarbon-nitrogen_non-peptide_hydrolases_a9d1.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b>Carbon-nitrogen non-peptide <a href="../../../h/y/d/Hydrolase.html" title="Hydrolase">hydrolases</a> (<a href="../../../e/c/_/EC_number_9459.html" title="EC number">EC</a> 3.5)</b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><a href="../../../a/m/i/Amidohydrolase.html" title="Amidohydrolase">Amidohydrolase</a>: <a href="../../../a/s/p/Asparaginase.html" title="Asparaginase">Asparaginase</a>, <a href="../../../a/s/p/Aspartoacylase.html" title="Aspartoacylase">Aspartoacylase</a>, <a href="../../../a/s/p/Aspartylglucosaminidase.html" title="Aspartylglucosaminidase">Aspartylglucosaminidase</a>, <strong class="selflink">Beta-lactamase</strong>, <a href="../../../f/a/a/FAAH_40db.html" title="FAAH">Fatty acid amide hydrolase</a>, <a href="../../../g/l/u/Glutaminase.html" title="Glutaminase">Glutaminase</a>, <a href="../../../h/i/s/Histone_deacetylase.html" title="Histone deacetylase">Histone deacetylase</a>, <a href="../../../u/r/e/Urease.html" title="Urease">Urease</a></p>
<p><a href="../../../a/m/i/Aminohydrolase.html" title="Aminohydrolase">Aminohydrolase</a>: <a href="../../../a/d/e/Adenosine_deaminase.html" title="Adenosine deaminase">Adenosine deaminase</a>, <a href="../../../a/m/p/AMP_deaminase_dfb3.html" title="AMP deaminase">AMP deaminase</a>, <a href="../../../g/t/p/GTP_cyclohydrolase_I_5d05.html" title="GTP cyclohydrolase I">GTP cyclohydrolase I</a></p>
<p><a href="../../../a/r/g/Arginase.html" title="Arginase">Arginase</a>, <a href="../../../t/h/i/Thiaminase.html" title="Thiaminase">Thiaminase II</a>, <a href="../../../n/i/t/Nitrilase.html" title="Nitrilase">Nitrilase</a></p>
</div>
</div>

<!-- 
Pre-expand include size: 51630 bytes
Post-expand include size: 17166 bytes
Template argument size: 9025 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../b/e/t/Beta-lactamase.html">http://en.wikipedia.org../../../b/e/t/Beta-lactamase.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../c/l/e/Category%7ECleanup_from_October_2006_e949.html" title="Category:Cleanup from October 2006">Cleanup from October 2006</a></span> | <span dir='ltr'><a href="../../../a/l/l/Category%7EAll_pages_needing_cleanup_2b7d.html" title="Category:All pages needing cleanup">All pages needing cleanup</a></span> | <span dir='ltr'><a href="../../../m/i/c/Category%7EMicrobiology_df2c.html" title="Category:Microbiology">Microbiology</a></span> | <span dir='ltr'><a href="../../../e/c/_/Category%7EEC_3.5.2_cc1f.html" title="Category:EC 3.5.2">EC 3.5.2</a></span> | <span dir='ltr'><a href="../../../b/e/t/Category%7EBeta-lactam_antibiotics_574a.html" title="Category:Beta-lactam antibiotics">Beta-lactam antibiotics</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../b/e/t/Beta-lactamase.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../b/e/t/Talk%7EBeta-lactamase_2e72.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Beta-lactamase">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/%CE%B2/-/l/%CE%B2-Lactamase_0261.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../fr/b/%C3%AA/t/B%C3%AAta-lactamase.html">FranÃ§ais</a>
	      </li>
	      	      <li>
	      <a href="../../../../he/%D7%91/%D7%98/%D7%90/%D7%91%D7%98%D7%90_%D7%9C%D7%A7%D7%98%D7%9E%D7%90%D7%96.html">×¢××¨××ª</a>
	      </li>
	      	      <li>
	      <a href="../../../../nl/p/e/n/Penicillinase.html">Nederlands</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/b/e/t/Beta-laktamazy.html">Polski</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 21:38, 7 April 2007 by Wikipedia user <a href="../../../a/l/e/User%7EAle_jrb_edf9.html" title="User:Ale jrb">Ale jrb</a>. Based on work by Wikipedia user(s) <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../d/e/l/User%7EDeLarge_49dd.html" title="User:DeLarge">DeLarge</a>, <a href="../../../l/e/n/User%7ELennert_B_2b71.html" title="User:Lennert B">Lennert B</a>, <a href="../../../a/l/-/User%7EAl-Bargit_ecde.html" title="User:Al-Bargit">Al-Bargit</a>, <a href="../../../p/r/e/User%7EPreetikapoor0_ca32.html" title="User:Preetikapoor0">Preetikapoor0</a>, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, <a href="../../../f/i/r/User%7EFirsfron_bff1.html" title="User:Firsfron">Firsfron</a>, <a href="../../../g/a/k/User%7EGak_da6b.html" title="User:Gak">Gak</a>, <a href="../../../r/e/e/User%7EReedy_Boy_3c7f.html" title="User:Reedy Boy">Reedy Boy</a>, <a href="../../../r/j/f/User%7ERJFJR_0643.html" title="User:RJFJR">RJFJR</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, Aeris gd, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../g/a/t/User%7EGAThrawn22_073d.html" title="User:GAThrawn22">GAThrawn22</a>, <a href="../../../y/u/r/User%7EYurikBot_b393.html" title="User:YurikBot">YurikBot</a>, <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>, <a href="../../../k/a/a/User%7EKaarel_340a.html" title="User:Kaarel">Kaarel</a>, <a href="../../../s/p/a/User%7ESpaully_efd5.html" title="User:Spaully">Spaully</a>, <a href="../../../d/e/l/User%7EDelldot_cc92.html" title="User:Delldot">Delldot</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../k/b/i/User%7EKBi_bd39.html" title="User:KBi">KBi</a>, <a href="../../../e/l/e/User%7EEleassar777_7cf2.html" title="User:Eleassar777">Eleassar777</a>, <a href="../../../e/r/a/User%7EEras-mus_f9f9.html" title="User:Eras-mus">Eras-mus</a>, <a href="../../../a/l/p/User%7EAlphax_a96c.html" title="User:Alphax">Alphax</a>, <a href="../../../d/r/a/User%7EDragonflySixtyseven_c6ee.html" title="User:DragonflySixtyseven">DragonflySixtyseven</a>, <a href="../../../d/w/m/User%7EDwmyers_463f.html" title="User:Dwmyers">Dwmyers</a> and <a href="../../../m/a/r/User%7EMarj_Tiefert_437d.html" title="User:Marj Tiefert">Marj Tiefert</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
